Advertisement

Daré Bioscience, Inc. DARE

Set alert

Price alert · DARE

All alert types
0.70 USD +0.02 +2.66%

At close · Oct 30

0.67 -0.03 -4.16%

After hours · Oct 30, 7:24 PM ET

Bid
0.69 × 2
Ask
0.70 × 10
0.67 Day range 0.7026
0.644 52-week range 3.27
YTD
-63.75%
1 year
-63.75%
Open
0.7026
Prev close
0.6815
Mkt cap
13.76M
Vol
654.01K
Avg vol
496.64K
EPS
-0.71
P/E
0.00
Div yield
0.00%
More statistics
Low
0.67
High
0.7026
Forward P/E
-2.35
Beta
1.34
Short ratio
0.64
Inst. own
7.59%
Dividend
0.00
Ex-div date
50-d avg
3.53
200-d avg
4.07
1y target
21.33

5Y chart

Chart tools
Interval

Events in this range
  • Aug 10, 2023Earnings: -1.2; estimate -1.2; surprise 0%
  • Nov 9, 2023Earnings: -1.08; estimate -1.2; surprise 10%
  • Mar 28, 2024Earnings: -0.72; estimate -1.44; surprise 50%
  • May 14, 2024Earnings: -0.84; estimate -0.72; surprise -16.67%
  • May 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Jul 1, 2024Split: 1 for 12
  • Aug 12, 2024Earnings: 1.52; estimate -0.57; surprise 366.67%
  • Aug 14, 2024Downgrade: Maxim Group · Buy → Hold
  • Aug 16, 2024Rating: Jones Trading · Buy → Buy
  • Oct 24, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Nov 14, 2024Earnings: -0.55; estimate -0.6; surprise 8.33%
  • Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (88)
NameDateAgo
SMA: BearishJul 13, 20263 months ago
MACD: Sell SignalJul 6, 20263 months ago
SMA: BullishJun 8, 20264 months ago
SMA: BearishJun 1, 20265 months ago
SMA: BearishJun 1, 20265 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BullishMar 30, 20267 months ago
MACD: Buy SignalMar 30, 20267 months ago
MACD: Sell SignalFeb 9, 20268 months ago
SMA: BearishJan 12, 20269 months ago
SMA: BullishJan 5, 202610 months ago
SMA: BearishDec 29, 202510 months ago
SMA: BearishDec 15, 202510 months ago
SMA: BullishDec 8, 202510 months ago
SMA: BullishDec 8, 202510 months ago
MACD: Buy SignalDec 8, 202510 months ago
MACD: Sell SignalNov 17, 202511 months ago
SMA: BearishOct 13, 20251 year ago
SMA: BullishSep 29, 20251 year ago
MACD: Buy SignalSep 29, 20251 year ago
RSI: OversoldAug 4, 20251 year ago
MACD: Sell SignalJun 23, 20251 year ago
SMA: BearishJun 16, 20251 year ago
SMA: BearishJun 9, 20251 year ago
SMA: BullishJun 2, 20251 year ago
SMA: BullishMay 26, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BullishApr 21, 20251 year ago
SMA: BearishFeb 24, 20251 year ago
SMA: BullishFeb 17, 20251 year ago
SMA: BearishFeb 3, 20251 year ago
SMA: BullishJan 27, 20251 year ago
SMA: BearishJan 20, 20251 year ago
SMA: BullishJan 13, 20251 year ago
MACD: Buy SignalDec 23, 20241 year ago
MACD: Sell SignalDec 16, 20241 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BullishOct 28, 20242 years ago
SMA: BullishOct 14, 20242 years ago
MACD: Buy SignalOct 7, 20242 years ago
SMA: BearishSep 2, 20242 years ago
SMA: BullishAug 26, 20242 years ago
MACD: Sell SignalJul 1, 20242 years ago
SMA: BearishJun 24, 20242 years ago
SMA: BearishJun 24, 20242 years ago
SMA: BullishMay 13, 20242 years ago
SMA: BullishMay 13, 20242 years ago
MACD: Buy SignalMay 13, 20242 years ago
MACD: Sell SignalApr 29, 20242 years ago
SMA: BearishApr 15, 20242 years ago
SMA: BearishApr 15, 20242 years ago
SMA: BullishFeb 19, 20242 years ago
SMA: BullishJan 22, 20242 years ago
SMA: BearishJan 15, 20242 years ago
SMA: BullishJan 1, 20242 years ago
MACD: Buy SignalDec 11, 20232 years ago
RSI: OversoldSep 4, 20233 years ago
RSI: OversoldJul 31, 20233 years ago
SMA: BearishJun 5, 20233 years ago
MACD: Sell SignalJun 5, 20233 years ago
SMA: BullishMay 29, 20233 years ago
MACD: Buy SignalMay 29, 20233 years ago
SMA: BearishMay 22, 20233 years ago
SMA: BearishMay 22, 20233 years ago
SMA: BullishMay 15, 20233 years ago
SMA: BullishMay 15, 20233 years ago
SMA: BearishApr 3, 20233 years ago
MACD: Sell SignalApr 3, 20233 years ago
SMA: BullishMar 27, 20233 years ago
SMA: BearishMar 6, 20233 years ago
SMA: BearishMar 6, 20233 years ago
SMA: BullishFeb 27, 20233 years ago
SMA: BearishFeb 20, 20233 years ago
SMA: BullishJan 9, 20233 years ago
SMA: BullishJan 2, 20233 years ago
MACD: Buy SignalNov 14, 20223 years ago
MACD: Sell SignalOct 3, 20224 years ago
SMA: BearishSep 19, 20224 years ago
SMA: BullishSep 12, 20224 years ago
SMA: BearishAug 15, 20224 years ago
SMA: BullishAug 1, 20224 years ago
SMA: BearishJul 18, 20224 years ago
SMA: BullishJul 4, 20224 years ago
SMA: BearishJun 27, 20224 years ago
SMA: BullishMay 30, 20224 years ago
SMA: BearishApr 4, 20224 years ago
SMA: BullishMar 14, 20224 years ago

Key statistics

Market cap
27.75M
Enterprise value
16.85M
Trailing P/E
0.00
Forward P/E
-2.35
PEG ratio
0.00
Price / sales
9.77
Price / book
0.00
EPS (TTM)
-0.58
Beta
1.34
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-253.60%
Revenue (TTM)
2.84M
Revenue growth
0.00%
Free cash flow
-20.98M
Total cash
16.41M
Total debt
5.83M
Return on equity
0.00%
Shares outstanding
8.70M
Short % of float
0.35%
50-day average
3.53
200-day average
4.07

Analyst view

Consensus: buy

Buy
Price target (mean) 21.33 +2949.4% upside
Target (low)
12.00
Target (mean)
21.33
Target (high)
39.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.63333.

Earnings history

Financials — quick view

All financials
DARE Revenue — quarterly 187.55K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DARE Net income — quarterly -2.98M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DARE EPS — quarterly -0.20
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DARE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.60-0.55+0.05+8.33%
Aug 12, 2024Jun 1, 2024-0.571.52+2.09+366.67%
May 14, 2024Mar 1, 2024-0.72-0.84-0.12-16.67%
Mar 28, 2024Dec 1, 2023-1.44-0.72+0.72+50.00%
Nov 9, 2023Sep 1, 2023-1.20-1.08+0.12+10.00%
Aug 10, 2023Jun 1, 2023-1.20-1.200.000.00%

Upgrades / downgrades

DARE analyst upgrades and downgrades
DateFirmActionFromTo
Dec 17, 2024HC Wainwright & Co.reitBuyBuy
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Oct 24, 2024HC Wainwright & Co.reitBuyBuy
Aug 16, 2024Jones TradingmainBuyBuy
Aug 14, 2024Maxim GroupdownBuyHold
May 15, 2024HC Wainwright & Co.reitBuyBuy

About Daré Bioscience, Inc.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DARE — it syncs with the Stock Master app.

Institution ownership

DARE institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc3.31%287,725917.84KSep 29, 2024
AMH Equity Ltd.1.15%100,000319.00KSep 29, 2024
Geode Capital Management, LLC1.02%89,060284.10KSep 29, 2024
Renaissance Technologies, LLC0.74%64,395205.42KSep 29, 2024
State Street Corporation0.27%23,51575.01KSep 29, 2024
Commonwealth Equity Services, LLC0.20%17,48655.78KSep 29, 2024

Fund ownership

DARE fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.37%205,801656.50KSep 29, 2024
Vanguard Extended Market Index Fund0.91%78,984251.96KSep 29, 2024
Fidelity Extended Market Index Fund0.56%48,543154.85KOct 30, 2024
Fidelity Total Market Index Fund0.18%15,46149.32KOct 30, 2024
Fidelity Series Total Market Index Fund0.14%11,77437.56KOct 30, 2024
Price (T.Rowe) U.S. Equities Trust0.12%10,49133.47KSep 29, 2024
Advertisement